These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Length of the linking domain of human pro-tumor necrosis factor determines the cleavage processing. Tang P; Hung M-C ; Klostergaard J Biochemistry; 1996 Jun; 35(25):8226-33. PubMed ID: 8679577 [TBL] [Abstract][Full Text] [Related]
3. Expression of an exogenous tumor necrosis factor (TNF) gene in TNF-sensitive cell lines confers resistance to TNF-mediated cell lysis. Vanhaesebroeck B; Decoster E; Van Ostade X; Van Bladel S; Lenaerts A; Van Roy F; Fiers W J Immunol; 1992 May; 148(9):2785-94. PubMed ID: 1374099 [TBL] [Abstract][Full Text] [Related]
4. A part of the transmembrane domain of pro-TNF can function as a cleavable signal sequence that generates a biologically active secretory form of TNF. Ishisaka R; Sato N; Tanaka K; Takeshige T; Iwata H; Klostergaard J; Utsumi T J Biochem; 1999 Aug; 126(2):413-20. PubMed ID: 10423538 [TBL] [Abstract][Full Text] [Related]
5. In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor. Karp SE; Hwu P; Farber A; Restifo NP; Kriegler M; Mulé JJ; Rosenberg SA J Immunol; 1992 Sep; 149(6):2076-81. PubMed ID: 1517571 [TBL] [Abstract][Full Text] [Related]
6. Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells. Nyormoi O; Wang Z; Doan D; Ruiz M; McConkey D; Bar-Eli M Mol Cell Biol; 2001 Aug; 21(15):4856-67. PubMed ID: 11438643 [TBL] [Abstract][Full Text] [Related]
7. Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor. Involvement of individual cysteine-rich repeats. Corcoran AE; Barrett K; Turner M; Brown A; Kissonerghis AM; Gadnell M; Gray PW; Chernajovsky Y; Feldmann M Eur J Biochem; 1994 Aug; 223(3):831-40. PubMed ID: 8055960 [TBL] [Abstract][Full Text] [Related]
8. Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. Solomon KA; Pesti N; Wu G; Newton RC J Immunol; 1999 Oct; 163(8):4105-8. PubMed ID: 10510344 [TBL] [Abstract][Full Text] [Related]
9. Processing of tumor necrosis factor by the membrane-bound TNF-alpha-converting enzyme, but not its truncated soluble form. Itai T; Tanaka M; Nagata S Eur J Biochem; 2001 Apr; 268(7):2074-82. PubMed ID: 11277930 [TBL] [Abstract][Full Text] [Related]
10. Site-directed mutational analysis of human tumor necrosis factor-alpha receptor binding site and structure-functional relationship. Zhang XM; Weber I; Chen MJ J Biol Chem; 1992 Nov; 267(33):24069-75. PubMed ID: 1331108 [TBL] [Abstract][Full Text] [Related]
11. Cytotoxic activities of recombinant soluble murine lymphotoxin-alpha and lymphotoxin-alpha beta complexes. Mackay F; Bourdon PR; Griffiths DA; Lawton P; Zafari M; Sizing ID; Miatkowski K; Ngam-ek A; Benjamin CD; Hession C; Ambrose CM; Meier W; Browning JL J Immunol; 1997 Oct; 159(7):3299-310. PubMed ID: 9317128 [TBL] [Abstract][Full Text] [Related]
12. Identification of tumor necrosis factor (TNF) amino acids crucial for binding to the murine p75 TNF receptor and construction of receptor-selective mutants. Ameloot P; Fiers W; De Bleser P; Ware CF; Vandenabeele P; Brouckaert P J Biol Chem; 2001 Oct; 276(40):37426-30. PubMed ID: 11448951 [TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells. Pócsik E; Duda E; Wallach D J Inflamm; 1995; 45(3):152-60. PubMed ID: 8597870 [TBL] [Abstract][Full Text] [Related]
14. In vitro processing of human tumor necrosis factor-alpha. Robache-Gallea S; Morand V; Bruneau JM; Schoot B; Tagat E; Réalo E; Chouaib S; Roman-Roman S J Biol Chem; 1995 Oct; 270(40):23688-92. PubMed ID: 7559538 [TBL] [Abstract][Full Text] [Related]
15. Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein. Bauer S; Adrian N; Williamson B; Panousis C; Fadle N; Smerd J; Fettah I; Scott AM; Pfreundschuh M; Renner C J Immunol; 2004 Mar; 172(6):3930-9. PubMed ID: 15004201 [TBL] [Abstract][Full Text] [Related]
16. Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo. Li Q; Li L; Shi W; Jiang X; Xu Y; Gong F; Zhou M; Edwards CK; Li Z Cancer Immunol Immunother; 2006 Dec; 55(12):1470-9. PubMed ID: 16555058 [TBL] [Abstract][Full Text] [Related]
17. Novel muteins of human tumor necrosis factor alpha. Ito R; Matsumoto H; Uchida K; Kubo T; Tsukii Y; Endo T; Kaji A Biochim Biophys Acta; 1991 Apr; 1096(3):245-52. PubMed ID: 2018798 [TBL] [Abstract][Full Text] [Related]
18. Expression and characterization of bioactive recombinant ovine TNF-alpha: some species specificity in cytotoxic response to TNF. Green IR; Fiskerstrand C; Bertoni G; Roy DJ; Peterhans E; Sargan DR Cytokine; 1993 May; 5(3):213-23. PubMed ID: 8218933 [TBL] [Abstract][Full Text] [Related]